Severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic that has caused approximately 300 000 deaths globally. Disseminated intravascular coagulopathy and other COVID-19–associated coagulopathies occur among patients with severe SARS-CoV-2 infections.1 Potentially lethal hypercoagulability is an unusual, poorly defined COVID-19–associated coagulopathy presentation.2,3 We found that more than half of patients admitted to the intensive care unit (ICU) of Baylor St Luke’s Medical Center developed clinically significant thromboses that were associated with hypercoagulable thromboelastographic (TEG) parameters alone.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: May 11, 2020.
Published: June 5, 2020. doi:10.1001/jamanetworkopen.2020.11192
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Mortus JR et al. JAMA Network Open.
Corresponding Author: Todd K. Rosengart, MD, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 1 Baylor Plaza, MS: BCM 390, Houston, TX 77030 (email@example.com).
Author Contributions: Drs Mortus and Rosengart had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Mortus, Manek, Loor, Cruz, Trautner, Rosengart.
Acquisition, analysis, or interpretation of data: Mortus, Manek, Brubaker, Rosengart.
Drafting of the manuscript: Mortus, Manek, Brubaker, Cruz, Rosengart.
Critical revision of the manuscript for important intellectual content: Mortus, Manek, Brubaker, Loor, Trautner, Rosengart.
Statistical analysis: Mortus.
Administrative, technical, or material support: Brubaker, Loor, Trautner.
Conflicts of Interest Disclosures: Dr Cruz reported being the founder of A2 Therapeutics and owning patent No. 7879793. Dr Trautner reported receiving grants from the Agency for Healthcare Research and Quality, Department of Veterans Affairs (VA) Health Services Research and Development Service, Rehabilitation Research and Development, and Zambon Pharmaceuticals and personal fees from Paratek outside the submitted work. No other disclosures were reported.
Funding/Support: Dr Brubaker is supported by grant No. T32 HL139425 from the National Institutes of Health and National Heart, Lung, and Blood Institute. Dr Trautner is supported in part by grant No. 13-413 from the Center for Innovations in Quality, Effectiveness and Safety at the Michael E. DeBakey VA Medical Center, Houston, Texas. Dr Cruz is supported in part by the Merit Review Award I01 BX002551 from the US Department of Veterans Affairs Biomedical Laboratory Research and Development Service.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The contents of this manuscript do not represent the views of the Department of Veterans Affairs or the US government.
Additional Contributions: Wei Qi, MS, provided statistical analysis for this study. Miriam King, MEd, assisted with manuscript preparation. Robert Southard, MD, and Yesenia Rojas-Khalil, MD (Baylor St Luke Medical Center); and Laila Eugenia Woc-Colburn, MD, and Meredith Reyes, MD (Baylor College of Medicine) assisted in developing material related to this study. They were not compensated for their contributions.
You currently have no searches saved.
You currently have no courses saved.